CASE 3 63 yo man HIV positive G1a chronic Hepatitis C… Recent HIV history TDF/FTC/RTV/Atazanavir with CD4 480 and HIV viral load<40.

Slides:



Advertisements
Similar presentations
Protease and Polymerase Inhibitors for the Treatment of Hepatitis C
Advertisements

Page Up to Reverse  Employee Health  Page Down to Advance  Employee Health 
Christophe Hézode Hôpital Henri Mondor, Créteil, France Paris, 30 January 2012 Triple therapy today: Safety management in clinical practice.
Ardis Ann Moe UCLA CARE clinic/NEVHC Van Nuys 21 June 2014
Edited by Morris Sherman MD BCh PhD FRCP(C) Associate Professor of Medicine University of Toronto Protease Inhibitors in Chronic Hepatitis C: An Update.
CASE 2 48 yo man IVDU in past….last used 27 yrs ago Stable social situation Currently receiving social assistance with provincial drug coverage No comorbid.
Liver Disease and Thalassaemia George Constantinou.
Case scenario 3 Clinical Breakout Session Smallpox Vaccine Adverse Event Workshop January 22-23, 2003.
Hepatitis web study H EPATITIS W EB S TUDY Use of & Telaprevir (Incivek) in the Treatment of Chronic Hepatitis C Virus Presentation Prepared by: David.
A Painful, Purpuric Rash
Hepatitis web study Hepatitis web study Sofosbuvir + Ribavirin to Prevent Post-Transplant HCV Recurrence Phase 2 Curry MP, et al. Gastroenterology. 2015;148:100-7.
Skin and Oral Manifestations of HIV Infection
ALAN FRANCISCUS EXECUTIVE DIRECTOR, HEPATITIS C SUPPORT PROJECT EDITOR-IN-CHIEF, HCV ADVOCATE WEBSITE JOIN ME ON TWITTER & FACEBOOK – HCVADVOCATE BLOG:
CASE 3 55 yo man HIV positive 2008 CD4 320/23% Viral load 123,557 c/ml Genotype clear TDF/FTC/EFV initiated.
CASE 4 67 yo man HIV Hypertensive CD4 on diagnosis 110/7% AZT initiated soon after diagnosis.
CASE 1 55 yo man…Baker HIV+ since 1996 Refused bloodwork over the years as was ‘Feeling fine’ Oral hairy leukoplakia noted on oral biopsy in 2001.
VIRTUAL MEDZONE Your Resource for HIV Related Innovative Medical Communication.
NICE Guidelines on the Use of Ribavirin and Interferon Alpha for Hepatitis C Matt Johnson and Dr. Hunt / Asante / Jenkins.
Genital Herpes.
Atopic & Contact Dermatitis; Scaly Dermatoses Spring Term 2006 Lab Week 3.
Prabhdeep Sidhu Candidate PharmD 2015 Western University of Health Sciences Mar 28, 2014.
Beyond Skin Small Group Teaching Problem Based Learning Dermatology Department College of Medicine King Saud University.
CASE 2 49 yo man HIV Bipolar 2 disorder highlighted by major depression with a few serious suicide attempts and necessitating multiple hospital admissions.
NYU Medical Grand Rounds Clinical Vignette Alexander Jow, PGY-3 February 21, 2012 U NITED S TATES D EPARTMENT OF V ETERANS A FFAIRS.
LDV/SOF 90/400 mg qd Non-randomised Open-label N = 21 W12 SVR 12 NIAID SYNERGY GT4 Kohli A. Lancet Infect Dis 2015; Juky 15, ePub ahead of print ≥ 18 years.
OBV/PTV/r + DSV + RBV OBV/PTV/r + DSV Randomisation* 1 : 1 Open label years Chronic HCV infection Genotype 1b Prior failure to PEG-IFN + RBV HCV.
Egyptian Ancestry  Design  Objective –SVR 12 (HCV RNA < 25 IU/ml), with 95% CI SOF 400 mg qd + RBV Randomised 1 : 1 Open-label Egyptian Ancestry Study:
How to manage G1 relapsers and non-responders George V. Papatheodoridis, MD Associate Professor in Medicine & Gastroenterology 2nd Department of Internal.
CASE 3 48 yo man HIV positive/HEP C positive 12 yrs ago Tenofovir/FTC/RTV/Lopinavir x 7 yrs CD4 310/40% HIV Viral Load
FISSION  Design  Objective –Non inferiority of SOF + RBV : SVR 12 (2-sided significance level of 5%, lower margin of the 95% CI for the difference =
All About Blood Borne Pathogens
REGISTRAR: DR GS HURTER CONSULTANT: DR JCJ VAN VUUREN FIRM: 3 MILITARY HOSPITAL ATYPICAL MANIFESTATION OF HEPATITIS A.
Reddy KR. Lancet Infect Dis. 2015;15:27-35 ATTAIN SMV + TVR placebo + PEG-IFN + RBV TVR + SMV placebo + PEG-IFN + RBV Randomisation* 1 : 1 Double-blind.
SIRIUS Placebo LDV/SOF + placebo Randomisation* 1 : 1 Double-blind SIRIUS Study: LDV/SOF ± RBV for genotype 1 and cirrhosis with non response to prior.
Prophylaxis of Opportunistic Infections
CASE 3 62 yo man Genotype 1b chronic hepatitis C Cirrhosis No previous ascites/encephalopathy OGD revealed a few very small esophageal varices.
CASE 3 52 yo man HIV positive 1999 CD4 nadir 50 Smoker 35 pack yrs…quit 2005 COPD…chronic bronchitis Diabetic, Hypertensive, Hyperlipidemic.
Blood borne Pathogens. Background  Occupational Safety and Health Administration (OSHA)  Blood borne pathogen standard developed December 6, 1991 
Chicken Pox & Shingles By Leah Olson.
CASE 2 58 yo man IVDU in past….last used 35 yrs ago Genotype 1a Chronic Hepatitis C Type II Diabetes Private drug plan coverage.
CASE 3 48 yo man HIV positive/HEP C positive 12 yrs. ago Tenofovir/FTC/RTV/Lopinavir x 7 yrs. CD4 310/40% HIV Viral Load
CASE 2 54 yo man…HIV PCP Cryptospordiasis Chronic HepC Genotype 1a Biopsy… 2/4 activity, 3/4scarring CD4 40 No baseline genotype.
Case Report D.Choe 1/20/16. History 32F with history of depressive symptoms, bipolar disorder, pw itchy and now painful rash for approx 1 week, worsening.
Dore G. J Hepatol 2016; 64:19-28 MALACHITE TVR + PEG-IFN + RBV Randomisation Open-label years HCV genotype 1 HCV RNA > 10,000 IU/ml Naïve (MALACHITE-I)
CASE 1 54 yo man HIV Generalized Anxiety/OCD VL 15,185 CD4 ranges from Baseline Genotype clear.
CASE 1 54 yo man HIV positive 8 yrs ago Tenofovir/FTC/RTV/Atazanavir x 4 yrs Previously documented NNRTI resistance with Y181C, G190A,and mixed m184v/wt.
Chapter 14: Bloodborne Pathogens. Bloodborne pathogens are transmitted through contact with blood or other bodily fluids Hepatitis, especially hepatitis.
Hepatitis C Past, present and future Salil Singh Consultant Gastroenterologist, RBH
Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C Edward J. Gane, M.D., Catherine A. Stedman, M.B., Ch.B. New Engl J Med 2013;
CASE 4 44 yo man HIV positive 2010 CD4 400 on diagnosis Initiated Abacavir/3TC/Dolutegravir in /2013 CD4 600 HIV viral load
Adefovir Suppresses HBV DNA Levels in Lamivudine-Resistant HIV/HBV Patients Slideset on: Benhamou Y, Thibault V, Vig P, et al. Safety and efficacy of adefovir.
Case Report AK Liver biopsy total length 6 mm suggestiv for
Drug Induced Liver Disease Tutoring
Treatment of Latent TB Infection (LTBI)
Severe Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) induced by telaprevir.   I. Gallais Sérézal1, M. Delage1, V. Grando-Lemaire2, A. Lévy3,
Sofosbuvir plus Peg-Interferon and Ribavirin in Treatment Experienced Patients with Hepatitis C Virus and HIV Co-Infection Mehri Nikbin, MD Infectious.
Complicated cases David Fletcher, MD Department of Medicine University of Toronto.
Beyond Skin.
Too Early for an Itchy Rash Small Group Teaching Problem Based Learning Department of Dermatology College of Medicine King Saud University Riyadh.
PAEDIATRIC AIDS ¨     Acquired immunodeficiency Syndrome (AIDS) is caused by Human Immunodeficiency Virus type 1 and 2 ¨     World wide problem, more.
HIV molecule.
History 56 y/o male from Cuba newly diagnosed with hepatitis C genotype 2b in Jan 2008 No symptoms of decompensation.
Volume 56, Issue 2, Pages (February 2012)
ION-3 Study: LDV/SOF + RBV for naïve genotype 1
New HCV therapies on the horizon
VACS Risk Index Refinement and further validation
CLINICAL PROBLEM SOLVING
Comparison of INSTI vs EFV
Hemorrhagic varicella
Putting Your Skills to the Test
Presentation transcript:

CASE 3 63 yo man HIV positive G1a chronic Hepatitis C… Recent HIV history TDF/FTC/RTV/Atazanavir with CD4 480 and HIV viral load<40

CASE 3 Chronic Hepatitis C history Naïve…no secondary causes of liver disease F3 via non invasive methods Chooses to keep HIV meds the same and wants to try Telaprevir Very concerned about side effects/QOL during therapy Baseline HCVRNA 1.86 x 10e6

CASE 3 Response to PEG INF/RBV/Telaprevir Week 0 HCVRNA 1.86x10e6 Week 4 HCVRNA Detectable but <15 Week 8 HCVRNA <15 Develops rash at week 8…what information would you like?

CASE 3 Rash Mild, less than 50% BSA with maculopapular component on back of arms and upper back Intensely pruritic No associated constitutional symptoms No mucous membrane involvement Any questions regarding labs?

CASE 3 Labs CBC…no eosinophilia Liver enzymes/renal function unchanged from previous What would you do given rash?

CASE 3 Continues with PEG INF/RBV/Telaprevir as no concerning signs relating to rash Rash associated symptoms worsen with increasing pruritis despite local therapy with a steroid cream and Benadryl…keeping him awake causing increased agitation during the days and fatigue relating to insomnia and Benadryl effect Rash itself progresses to involve entire trunk, arms and legs to now encompass >50% body surface area (approx 65%) No constitutional symptoms, blistering, target lesions or mucous membrane involvement

CASE 3 End of week 10 of therapy with triple therapy What would you do?

CASE 3 End of week 10 of therapy with triple therapy Telaprevir discontinued and PEG INF/RBV continued Rash progressed a little further without alarming features for a further week and symptoms continued for 2 more weeks Do you think that we have increased risk of relapse given shorter course of Telaprevir?

CASE 3 Week 12 HCVRNA <15 Week 16 HCVRNA <15 Week 24 HCVRNA <15